Opus Genetics, Inc. (IRD)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$60.0M
Cash & Equivalents
$12.7M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$324M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-10-17 Pdufa —

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT05616793 Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interv... PHASE2 Recruiting 22
NCT07185256 Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) o... PHASE2 Recruiting 10

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-16 8-K Opus Genetics, Inc. (IRD) (CIK 0001228627) - EXHIBIT 99.1 EDGAR
2026-06-16 8-K Opus Genetics, Inc. (IRD) (CIK 0001228627) - EXHIBIT 99.1 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IRD.

SEC EDGAR Filings

All SEC filings for Opus Genetics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.